Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology...
share announcement

PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 644

Special Issue Editors

Dr. Alessio Rizzo

E-Mail
Guest Editor
Department of Nuclear Medicine, Candiolo Cancer Institute—FPO—IRCCS, Candiolo, Turin, Italy
Interests: PET/CT; theragnostics; prostate cancer; lymphoma; thyroid cancer
Prof. Dr. Giorgio Treglia

E-Mail Website
Guest Editor
Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
Interests: PET; nuclear medicine; hybrid imaging; meta-analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the swiftly advancing domain of functional imaging, novel radiopharmaceuticals are emerging as new headliners in the rapidly evolving fields of oncologic and inflammatory diseases, trying to bring the promise of a patient-tailored medicine to reality.

In this setting, new-generation radiopharmaceuticals are assuming great relevance both in studying different features of the disease, such as the tumour stroma in place of cancer cells’ metabolism through radiolabelled fibroblast activation protein inhibitors, and in treatment planning, individuating and quantifying the expression of specific therapeutic targets (e.g., PD-L1) in order to modulate treatments and predict their success.

We are pleased to invite you to contribute to this Special Issue,  PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases, which aims to collect the most interesting papers on the applications of novel radiopharmaceuticals in oncologic and inflammatory diseases.

In this Special Issue, original research articles and reviews are welcome. Pre-clinical or clinical studies, experimental or observational studies, and senior or young investigators will be considered for publication.

Dr. Alessio Rizzo
Prof. Dr. Giorgio Treglia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • PET/CT
  • radiopharmaceuticals
  • theragnostics
  • oncology
  • inflammation
  • personalised medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

13 pages, 3924 KiB  
Systematic Review
Meta-Analysis on the Prevalence and Significance of Incidental Findings in the Thyroid Gland Using Other PET Radiopharmaceuticals Beyond [18F]FDG
by Cesare Michele Iacovitti, Domenico Albano, Alessio Rizzo, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Pierpaolo Trimboli and Giorgio Treglia
Pharmaceuticals 2025, 18(5), 723; https://doi.org/10.3390/ph18050723 - 15 May 2025
Viewed by 319
Abstract
Background: Meta-analyses on the prevalence and significance of thyroid incidentalomas at PET (TIP) are available only about [18F]FDG. Focal TIP at [18F]FDG PET is not rare and may be malignant lesions in about one-third of cases. The aim [...] Read more.
Background: Meta-analyses on the prevalence and significance of thyroid incidentalomas at PET (TIP) are available only about [18F]FDG. Focal TIP at [18F]FDG PET is not rare and may be malignant lesions in about one-third of cases. The aim of this study is to perform a meta-analysis on the prevalence and clinical significance of TIP using other PET radiotracers beyond [18F]FDG. Methods: A comprehensive literature search of studies about TIP was carried out using four different databases, screened until 31 December 2024. Only original articles about TIP using radiopharmaceuticals other than [18F]FDG were selected. A proportion meta-analysis on the prevalence and clinical significance of TIP was carried out on a patient-based analysis using a random-effects model. Results: 21 studies (29,409 patients) were included in the meta-analysis. PET was performed using radiolabeled somatostatin analogues (SSA) [n = 5], choline [n = 6], prostate-specific membrane antigen (PSMA) [n = 7], or fibroblast activation protein inhibitors (FAPI) [n = 3]. The uptake pattern of TIP was described as focal, diffuse, or mixed/heterogeneous. The pooled prevalence of TIP was 5.6% for SSA-PET, 6.1% for choline-PET, 4.2% for PSMA-PET, and 3.6% for FAPI-PET. The final diagnosis of TIP with a diffuse pattern was a benign condition or represented a physiological uptake. Conversely, TIP with focal or mixed/heterogeneous pattern may represent a benign condition in most cases, but even a malignant lesion in 6–10% of cases. Conclusions: As for [18F]FDG, TIP using other radiopharmaceuticals is not rare. Most of them are benign, but those with focal or heterogeneous uptake patterns may represent a malignant lesion in some cases (even if the risk of malignancy is lower compared to [18F]FDG PET), thus requiring further evaluation. Further studies are warranted to better clarify the clinical impact of TIP detection. Full article
(This article belongs to the Special Issue PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop